Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: iSTAR Medical Receives CE Mark For Glaucoma Device

Executive Summary

MINIject has been approved in Europe for open-angle glaucoma patients.

You may also be interested in...



Minute Insight: AbbVie Bets Big On Glaucoma Market With iSTAR Purchase Deal

The pharmaceutical company has made a bold play to expand its presence in the device space, giving iSTAR upfront cash in a deal that grants it the right to buy iSTAR for almost half a billion dollars.

Execs On The Move: January 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

AI Medical Technology Doubles Down On Melanoma With Trials And Financing

Over the past month, the company has released positive clinical trial results and raised more cash, both of which will help on its way to combat melanoma.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel